Roles of cyclooxygenase 2 in sevoflurane- and olprinone-induced early phase of preconditioning and postconditioning against myocardial infarction in rat hearts

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 16, Issue 1, 2011, Pages 72-78

  Tosaka, Shinya ^a   Tosaka, Reiko ^b   Matsumoto, Shuhei ^b   Maekawa, Takuji ^b   Cho, Sungsam ^b   Sumikawa, Koji ^b  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

cyclooxygenase; myocardial ischemia; olprinone; sevoflurane

Indexed keywords

CYCLOOXYGENASE 2; LOPRINONE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PENTOBARBITAL; SEVOFLURANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARDIOTONIC AGENTS; CORONARY VESSELS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HEART; IMIDAZOLES; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; METHYL ETHERS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITROBENZENES; PYRIDONES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 79951485219     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410380208     Document Type: Article

References (29)

1. Gislason GH, Jacobsen S., Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 ; 113 (25). 2906-2913. (Pubitemid 44297231)
2. Salinas G., Rangasetty UC, Uretsky BF, Birnbaum Y. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther. 2007 ; 12 (2). 98-111. (Pubitemid 46836330)
3. Bolli R., Shinmura K., Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002 ; 55 (3). 506-519. (Pubitemid 34874945)
4. Tanaka K., Ludwig LM, Krolikowski JG, et al. Isoflurane produces delayed preconditioning against myocardial ischemia and reperfusion injury: role of cyclooxygenase-2. Anesthesiology. 2004 ; 100 (3). 525-531. (Pubitemid 38268868)
5. Lutz M., Liu H. Inhaled sevoflurane produces better delayed myocardial protection at48 versus 24 hours after exposure. Anesth Analg. 2006 ; 102 (4). 984-990.
6. Obal D., Dettwiler S., Favoccia C., Scharbatke H., Preckel B., Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg. 2005 ; 101 (5). 1252-1260. (Pubitemid 41531854)
7. Ludwig LM, Weihrauch D., Kersten JR, Pagel PS, Warltier DC Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. Anesthesiology. 2004 ; 100 (3). 532-539. (Pubitemid 38268869)
8. Alcindor D., Krolikowski JG, Pagel PS, Warltier DC, Kersten JR Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology. 2004 ; 100 (3). 547-554. (Pubitemid 38268871)
9. Penna C., Mancardi D., Tullio F., Pagliaro P. Postconditioning and intermittent bradykinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol. 2008 ; 103 (4). 368-377.
10. Satoh H., Endoh M. Effects of a new cardiotonic agent 1, 2-dihydro-6-methyl-2-oxo-5-[imidazo (1, 2-a) pyridine-6-yl]-3- pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle. Jpn J Pharmacol. 1990 ; 52 (2). 215-224. (Pubitemid 20070264)
11. Sanada S., Kitakaze M., Papst PJ, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors. Circulation. 2001 ; 104 (6). 705-710.
12. Matsumoto S., Cho S., Tosaka S., et al. Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway. Cardiovasc Drugs Ther. 2009 ; 23 (4). 263-270.
13. Ye Y., Keyes KT, Zhang C., Perez-Polo JR, Lin Y., Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol. 2010 ; 298 (5). H1454 - H1465.
14. Conzen PF, Vollmar B., Habazettl H., Frink EJ, Peter K., Messmer K. Systemic and regional hemodynamics of isoflurane and sevoflurane in rats. Anesth Analg. 1992 ; 74 (1). 79-88.
15. Patel HH, Hsu AK, Gross GJ COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci. 2004 ; 75 (2). 129-140. (Pubitemid 38553870)
16. Tosaka S., Makita T., Tosaka R., et al. Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth. 2007 ; 21 (2). 176-180. (Pubitemid 46692010)
17. Use T., Makita T., Ureshino H., et al. Milrinone administered before ischemia or just after reperfusion, attenuates myocardial stunning in anesthetized swine. Cardiovasc Drugs Ther. 2006 ; 20 (5). 327-334. (Pubitemid 44951330)
18. Gres P., Schulz R., Jansen J., Umschlag C., Heusch G. Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res. 2002 ; 55 (3). 626-632. (Pubitemid 34874957)
19. Sato H., Bolli R., Rokosh GD, et al. The cardioprotection of the late phase of ischemic preconditioning is enhanced by postconditioning via a COX-2-mediated mechanism in conscious rats. Am J Physiol Heart Circ Physiol. 2007 ; 293 (4). H2557 - H2564.
20. Hide EJ, Ney P., Piper J., Thiemermann C., Vane JR Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. Br J Pharmacol. 1995 ; 116 (5). 2435-2440.
21. Shinmura K., Tamaki K., Sato T., Ishida H., Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol. 2005 ; 288 (5). H2093 - H2101.
22. Bouwman RA, Musters RJ, van Beek-Harmsen BJ, de Lange JJ, Boer C. Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. Anesthesiology. 2004 ; 100 (3). 506-514. (Pubitemid 38268866)
23. Abbate A., Santini D., Biondi-Zoccai GGL, et al. Cyclooxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe ? Heart. 2004 ; 90 (4). 440-443. (Pubitemid 38406923)
24. Engelbrecht AM, Ellis B. Apoptosis is mediated by cytosolic phospholipase A2 during simulated ishaemia/reperfusioninduced injury in neonatal cardiac myocytes. Prostaglandins Leukot Essent Fatty Acids. 2007 ; 77 (1). 37-43. (Pubitemid 47248255)
25. Lada-Moldovan L., Kaloustian S., Bah TM, Girard SA, Dery MA, Rousseau G. Chronic treatment with celecoxib reduces infarct size. J Cardiovasc Pharmacol. 2009 ; 54 (1). 31-37.
26. Straino S., Salloum FN, Baldi A., et al. Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat. J Cardiovasc Pharmacol. 2007 ; 50 (5). 571-577. (Pubitemid 350146461)
27. Saeed SA, Ahmed S. New aspects of cyclooxygenase-2 inhibition in myocardial infarction and ischaemia. Res Commun Mol Pathol Pharmacol. 2005 ; 117-118: 167-178. (Pubitemid 351359793)
28. Kodani E., Shinmura K., Xuan YT, et al. Cyclooxygenase-2 does not mediate late preconditioning induced by activation of adenosine A1 or A3 receptors. Am J Physiol Heart Circ Physiol. 2001 ; 281 (2). H959 - H968.
29. Salloum FN, Hoke NN, Seropian IM, et al. Parecoxib inhibits apoptosis in acute myocardial infarction due to permaneny coronary ligation but not due to ischemia-reperfusion. J Cardiovasc Pharmacol. 2009 ; 53 (6). 495-498.